Drug Approval | August 05, 2021
Combinations of Sputnik V component with other vaccines demonstrate favourable results: RDIF
AstraZeneca, Sinopharm and Moderna were part of the study
AstraZeneca, Sinopharm and Moderna were part of the study
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The first batch will be shipped to the Gamaleya Center for the quality control
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Dr. Reddy's has the rights to distribute 250mn doses in India
The company is working closely with its six manufacturing partners in India
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Subscribe To Our Newsletter & Stay Updated
